Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.66 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.65 |
| ▸ | CXCL12 | P48061 | 8/20 | 0.65 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.64 |
| ▸ | KDR | P35968 | 1/20 | 0.62 |
| ▸ | ACHE | P22303 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25219790 | 1.00 | MAPT (0.67) | MAPTTRPV1NPC1RAB9APTPN1 | |
| SCHEMBL30383230 | 0.91 | MAPT (0.67) | MAPTTRPV1NPC1RAB9APTPN1 | |
| SCHEMBL30383417 | 0.91 | MAPT (0.67) | MAPTTRPV1NPC1RAB9APTPN1 | |
| SCHEMBL25190579 | 0.91 | MAPT (0.67) | MAPTTRPV1NPC1RAB9APTPN1 | |
| SCHEMBL25192148 | 0.91 | MAPT (0.67) | MAPTTRPV1NPC1RAB9APTPN1 | |
| SCHEMBL19782822 | 0.89 | KDR (0.78) | FGFR1CXCL12CXCR4KDRACHE | |
| SCHEMBL25200368 | 0.88 | MAPT (0.63) | MAPTTRPV1NPC1RAB9APTPN1 | |
| SCHEMBL25195567 | 0.88 | MAPT (0.63) | MAPTTRPV1NPC1RAB9APTPN1 | |
| SCHEMBL25192663 | 0.88 | MAPT (0.63) | MAPTTRPV1NPC1RAB9APTPN1 | |
| SCHEMBL30382801 | 0.88 | MAPT (0.63) | MAPTTRPV1NPC1RAB9APTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-11046657-B2 | Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-06-29 | — | — | US | disclosed |
| US-20200181093-A1 | Pyrimidinone Derivatives and Uses Thereof to Neutralize the Biological Activity of Chemokines | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2020-06-11 | — | — | US | disclosed |
| WO-2018011376-A1 | PYRIMIDINONE DERIVATIVES AND USES THEREOF TO NEUTRALIZE THE BIOLOGICAL ACTIVITY OF CHEMOKINES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - (FR) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181093-A1 | Pyrimidinone Derivatives and Uses Thereof to Neutralize the Biological Activity of Chemokines | CCL5, CXCR3, CXCL10 | MAPT 1279/4885TRPV1 457/4885NPC1 3576/4885 |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | MAPT 3297/4885TRPV1 3581/4885NPC1 1378/4885 |
| US-11046657-B2 | Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines | CCL5, CXCR3, CXCL10 | MAPT 1279/4885TRPV1 457/4885NPC1 3576/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | MAPT 3512/4885TRPV1 4225/4885NPC1 1908/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | MAPT 3512/4885TRPV1 4225/4885NPC1 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.